Status:

COMPLETED

Optimizing tDCS to Improve Dual Task Gait and Balance

Lead Sponsor:

Hebrew SeniorLife

Conditions:

Aging

Eligibility:

All Genders

65-85 years

Phase:

NA

Brief Summary

The objective of this study is to determine the acute effects of single sessions of optimized tDCS, conventional tDCS, and sham stimulation on dual task standing and walking in older adults who are fr...

Detailed Description

Standing and walking are almost always completed in unison with other cognitive tasks such as talking, reading or making decisions. The ability to perform this important type of "dual tasking" is crit...

Eligibility Criteria

Inclusion

  • Men and women aged 65-85 years
  • Poor dual task performance, defined as a preferred gait speed that is \>10% slower when walking and simultaneously performing verbalized serial subtractions (i.e., dual tasking), as compared to walking normally (i.e. single tasking)

Exclusion

  • Unwillingness to cooperate or participate in the study protocol
  • An inability to walk or stand for 30 continuous seconds without an assistive device
  • A diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder
  • Self-report of acute illness, injury or other unstable medical condition; Any report of severe lower-extremity arthritis or pain, physician-diagnosis of peripheral neuropathy, or other peripheral neuromuscular disease that may confound the effects of tDCS on gait or postural control
  • Use of antipsychotics, anti-seizure, benzodiazepines, or other neuroactive medications
  • Severe depression defined by a Geriatric Depression Scale score greater than 11;
  • Any report or physician-diagnosis of schizophrenia, bipolar disorder or other psychiatric illness
  • Contraindications to MRI or tDCS, including reported seizure within the past two years, use of neuro-active drugs, the risk of metal objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Key Trial Info

Start Date :

February 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 2 2023

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT04295798

Start Date

February 10 2020

End Date

March 2 2023

Last Update

January 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hebrew Rehabilitation Center

Roslindale, Massachusetts, United States, 02131